amonafide + cytarabine

Amonafide + cytarabine is a combination therapy investigated primarily for the treatment of secondary acute myeloid leukemia (sAML). Amonafide (also known as AS1413 or Xanafide) is a DNA intercalator and non–ATP-dependent topoisomerase II inhibitor that induces apoptosis by disrupting chromatin organization, evading common drug resistance mechanisms such as P-glycoprotein-mediated efflux. Cytarabine is an antimetabolite chemotherapeutic agent that inhibits DNA polymerase and incorporates into DNA, leading to direct DNA damage and inhibition of cell proliferation. The combination was studied in phase I–III clinical trials for sAML but did not demonstrate superior efficacy compared to standard regimens. Amonafide was originally developed by Xanthus Pharmaceuticals, later acquired by Antisoma, which discontinued its development after negative phase III results[2][3][4][5].

Other names

amonafide L-malatecytarabine